Literature DB >> 15661630

Ecstasy: pharmacology and neurotoxicity.

Jenny Morton1.   

Abstract

In part because it is amphetamine derived, ecstasy has inherited some of its parent compound's reputation for being neurotoxic. However, whereas amphetamine and methamphetamine undoubtedly cause irreversible brain damage with long-term use, the jury is still out on the party drug ecstasy. The deadly reputation of ecstasy has been fuelled by the tragic fates of healthy young clubbers who have died after taking the drug. However, compared with other recreational drugs, there have been very few ecstasy-related deaths. Further, there is little evidence for short-term neurotoxicity of ecstasy at recreational doses. That is not to say that ecstasy leaves the user neutral. Chronic ecstasy use causes depletion of serotonin, which has subtle but important long-term effects on cognition and mood. Although it seems unlikely that we will be faced with a generation of party goers who suffer from premature Parkinson's disease, so little is known about the long-term effects of ecstasy on mood, emotional states and cognitive function that at present we cannot predict what impact their use of ecstasy will have on the middle-age of the average ecstasy user.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661630     DOI: 10.1016/j.coph.2004.08.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  25 in total

1.  Ecstasy induced acute bilateral angle closure and transient myopia.

Authors:  Rajesh S Kumar; John Grigg; Adrian C Farinelli
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

Review 2.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

3.  Dexmedetomidine to control agitation and delirium from toxic ingestions in adolescents.

Authors:  Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

4.  The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI).

Authors:  Shahaf Edut; Vardit Rubovitch; Shaul Schreiber; Chaim G Pick
Journal:  Psychopharmacology (Berl)       Date:  2010-12-01       Impact factor: 4.530

5.  Effects of MDMA, methamphetamine and methylphenidate on repeated acquisition and performance in rats.

Authors:  M Galizio; P McKinney; D T Cerutti; R C Pitts
Journal:  Pharmacol Biochem Behav       Date:  2009-09-19       Impact factor: 3.533

6.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices.

Authors:  Carrie E John; Sara R Jones
Journal:  Neuropharmacology       Date:  2007-03-16       Impact factor: 5.250

8.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

9.  What's in a label? Ecstasy sellers' perceptions of pill brands.

Authors:  Micheline Duterte; Camille Jacinto; Paloma Sales; Sheigla Murphy
Journal:  J Psychoactive Drugs       Date:  2009-03

10.  Maximising the highs and minimising the lows: harm reduction guidance within ecstasy distribution networks.

Authors:  Camille Jacinto; Micheline Duterte; Paloma Sales; Sheigla Murphy
Journal:  Int J Drug Policy       Date:  2007-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.